Mission Statement, Vision, & Core Values of KORU Medical Systems, Inc. (KRMD)

You're looking past the stock ticker and into the soul of KORU Medical Systems, Inc. (KRMD), which is defintely the right move, especially as they project a 2025 net revenue of up to $41.0 million, representing a 22% growth at the high end of their guidance. But what does a medical device company-one focused on specialty infusion solutions-actually stand for when its core business is growing 30% in a quarter? Does a mission to empower patients with the freedom to truly live square with a market cap of around $178.47 million? We need to see if their Mission Statement, Vision, and Core Values are just corporate wallpaper or the actual engine driving that 61% to 63% gross margin guidance.

KORU Medical Systems, Inc. (KRMD) Overview

You need a clear picture of what KORU Medical Systems, Inc. is and where it stands right now, not a history lesson. The short answer is they are the global leader in home-based, large-volume subcutaneous infusion, and their business is accelerating, projecting revenues of up to $41.0 million for the full 2025 fiscal year.

The company, initially established in 1984 and later rebranded in 2018, is a medical technology firm focused on developing, manufacturing, and commercializing specialty infusion solutions. Their core mission is to improve the quality of life for patients with chronic illnesses like Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by enabling safe, effective, and easy self-administration of life-saving therapies at home. That's a powerful mission, and it drives a very sticky, recurring revenue model.

The entire business revolves around the Freedom Syringe Infusion System (often called the Freedom System). This system includes the Freedom60 and FreedomEdge syringe drivers, plus consumables like HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. They are currently supporting approximately 45,000 chronic patients annually with their at-home infusion needs. To understand more about the mechanics of their business model, you can check out KORU Medical Systems, Inc. (KRMD): History, Ownership, Mission, How It Works & Makes Money.

2025 Financial Performance: A Breakout Year

Honesty, the Q3 2025 earnings, reported in November 2025, show a company hitting its stride and then raising the bar. We're not talking about marginal gains here; we're seeing a significant acceleration in core business execution.

For the third quarter ended September 30, 2025, KORU Medical Systems, Inc. reported net revenues of $10.4 million, which is a strong 27% increase over the same period last year. This marks their second consecutive quarter with over $10 million in revenue. The core business, which is the Subcutaneous Immunoglobulin (SCIg) market, was the main driver, growing by a huge 30% year-over-year.

Here's the quick math on their momentum:

• Q3 2025 Net Revenue: $10.4 million (27% YoY growth)
• Core Business Revenue Growth: 30% in Q3 2025
• International Revenue Growth: A staggering 230% in Q3 2025
• Full-Year 2025 Guidance (Raised): $40.5 million to $41.0 million

The international segment is defintely the story here, with revenue growth accelerating to 230% in the third quarter alone, offsetting a temporary decline in U.S. domestic revenue due to distributor inventory adjustments. Plus, they are tightening up the bottom line: the net loss improved by 51% to only ($0.8) million for the quarter, and gross profit rose by 21% to $6.3 million. They are delivering positive cash flow from operations for the full year 2025, which is a key sign of financial health.

Leading the Subcutaneous Infusion Market

KORU Medical Systems, Inc. isn't just a player in the specialty infusion market; they are the acknowledged global leader in large-volume Subcutaneous Immunoglobulin (SCIg) drug delivery. Their focus on patient-centric design and ease-of-use with the Freedom System has allowed them to consistently outperform the robust underlying SCIg market growth. They've built a technological edge in developing user-friendly, portable, and ambulatory (at-home) infusion devices, which is exactly where healthcare is moving.

This leadership position isn't static, either. They are actively expanding their market reach through new Pharma Services and Clinical Trials (PST) collaborations, which creates opportunities to reach broader patient populations with their technology. They are also advancing their innovation pipeline, including plans for a 510(k) filing by the end of 2025 to add new drugs to the Freedom Infusion System. This strategy of defending their core market while expanding into new drug therapies and international geographies is why they are a standout in the MedTech space. Their success is driven by a clear, focused strategy, so you should find out more about what makes this company a leader.

KORU Medical Systems, Inc. (KRMD) Mission Statement

You're looking for a clear map of KORU Medical Systems, Inc.'s long-term strategy, and that starts with the mission. The company's mission is direct and powerful: to empower patients with the freedom to truly live. This isn't just a feel-good statement; it's the financial anchor for their entire business model, guiding product development, market expansion, and their recurring revenue base.

A mission statement's significance is simple: it dictates where capital goes and which risks are acceptable. For KORU Medical Systems, this mission translates directly into a focus on home-based care, which is a high-growth sector. Their strategic focus has delivered, with the company raising its full-year 2025 net revenues guidance to between $40.5 million and $41.0 million, representing a strong 20% to 22% year-over-year growth. That kind of growth is a defintely a clear indicator that their mission is resonating with the market.

Core Component 1: Empowering Patients with the Freedom to Live

The first and most human component of the mission is patient empowerment-giving back control to those with chronic conditions. This means shifting complex, time-consuming intravenous (IV) infusions from a hospital setting to the patient's home, or an ambulatory infusion center.

This focus is why KORU Medical Systems supports the at-home infusion needs of approximately 45,000 chronic and recurring patients each year. The goal is to maximize the patient's quality of life, offering the freedom to work, attend school, or simply be wherever they choose. This commitment to the patient experience is what drives the stickiness of their product ecosystem, which is critical for their razor-razor blade model where consumables drive recurring revenue.

• Maximize patient quality of life.
• Support home-based, self-administered care.
• Drive recurring revenue through patient loyalty.

Core Component 2: Innovative Large-Volume Subcutaneous Infusion Solutions

The mission is grounded in a specific technological advantage: innovative, patient-centric large volume subcutaneous (SCIg) infusion solutions. Their flagship product, the Freedom Syringe Infusion System, which includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, is a key differentiator. This technology allows for the safe, at-home delivery of large-volume drugs, primarily for conditions like Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

The company is not standing still; it is actively advancing its Novel Therapies pipeline. In 2025 alone, KORU Medical Systems is planning to submit two previously commercialized drugs for 510(k) clearance with the Freedom Infusion System. This expansion beyond the core immunoglobulin (Ig) market is adding an estimated $2.2 billion to their total addressable market (TAM), which is a huge opportunity. This innovation is what fuels the core business growth, which saw a 30% increase in the third quarter of 2025.

Core Component 3: Delivering High-Quality Products and Operational Excellence

A mission to empower patients is meaningless without a relentless commitment to quality and operational excellence. This is where the company's core value, 'Pursuit of Excellence,' comes into play. For a medical device company, quality is not a soft metric; it's a hard financial and regulatory requirement.

The quality of the Freedom System is evidenced by its high patient acceptance and adherence rates. The system boasts a 97% adherence rate, which is a phenomenal number in chronic care and directly supports the company's strong, recurring revenue stream. Here's the quick math: high adherence means consistent consumable sales, which is why the company maintains a strong full-year 2025 gross margin guidance of 61% to 63%. Furthermore, the company is focused on operational efficiency, reiterating its expectation for positive cash flow from operations for the full year 2025. This combination of patient-centric quality and fiscal discipline is what separates a good company from a great investment. If you want to dig deeper into the money behind this mission, you should be Exploring KORU Medical Systems, Inc. (KRMD) Investor Profile: Who's Buying and Why?

KORU Medical Systems, Inc. (KRMD) Vision Statement

You're looking for the true north of KORU Medical Systems, Inc., the thing that drives their strategy and, ultimately, their stock performance. The direct takeaway is that their vision is not a fluffy poster on the wall; it is a clear operational mandate to dominate the large volume subcutaneous infusion (SCIg) market by focusing intensely on patient ease-of-use and global expansion. This vision is directly fueling their revenue growth, which is guided to be between $40.5 million and $41.0 million for the full year 2025.

As a seasoned financial analyst, I see the mission-to develop, manufacture, and commercialize innovative and easy-to-use specialty infusion solutions that improve the lives of patients around the world-as the actionable blueprint for their vision of becoming a market leader. It maps directly to their product development and their recent aggressive international push. Honestly, a vision without a clear operational mission is just a wish. Theirs is a roadmap.

Innovative and Easy-to-Use Specialty Infusion Solutions

KORU Medical Systems' vision of market leadership starts with product innovation, specifically making complex subcutaneous immunoglobulin (SCIg) therapy simple. Their core product, the Freedom System, including the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, is the concrete example here. This focus isn't just about a better pump; it is about reducing the friction in home-based care, which is a massive trend in healthcare delivery.

The company's recent moves in their Novel Therapies business, which now includes Pharma Services and Clinical Trials, show this vision in action. They are actively collaborating with biopharmaceutical companies to customize the Freedom System for new drug categories, including oncology. This strategic pivot is defintely a high-leverage move. They are on track for a 510(k) submission to the FDA for an oncology drug collaboration, with anticipated commercial entry in the second half of 2026. That's a clear action tied to the innovation pillar.

• Focus on user-friendly design for home-based self-administration.
• Customizing the Freedom System for new drug applications.
• Advancing a U.S.-based oncology study for future market entry.

Improving Quality of Life for Patients Worldwide

The patient-centric component of the vision-improving quality of life-is the ethical and commercial engine. For a medical device company, patient outcomes are the ultimate measure of success, and they directly translate to market share and sustained revenue. KORU Medical Systems' core business, the subcutaneous immunoglobulin (SCIg) market, grew by 30% in the third quarter of 2025, a clear sign that their patient-focused solutions are resonating with both patients and prescribers.

What this financial data hides is the human impact: a patient using the Freedom System at home avoids a long, costly infusion center visit. That's a tangible improvement in life quality, which drives long-term customer loyalty and market share gains. The company's gross margin guidance for 2025 is strong at 61% to 63%, but maintaining this requires balancing quality and cost, a constant tension in the medical device space. You can dive deeper into this financial health in Breaking Down KORU Medical Systems, Inc. (KRMD) Financial Health: Key Insights for Investors.

Global Access and Market Leadership

The third pillar of the vision is global impact, which is where the near-term opportunity is most visible. KORU Medical Systems is not just a US story anymore. Their international revenue growth was a staggering 230% year-over-year in Q3 2025, albeit partially inflated by a large distributor stocking order.

Here's the quick math: Management is targeting to accelerate their overall market share in the international SCIg market from the mid-teens into the 40% range over the next several years, representing a $10 million to $20 million opportunity. This aggressive international expansion for the Freedom System is the key catalyst for their raised 2025 revenue guidance. They ended Q3 2025 with a healthy cash balance of $8.5 million, which supports this global push and continued R&D investment. That's a strong position for a growth-focused medtech firm.

Still, domestic revenue declined 5% in Q3 2025, which signals that international growth is currently compensating for some US market volatility, possibly due to distributor inventory adjustments. The vision requires both domestic stability and international acceleration to truly achieve market leadership.

KORU Medical Systems, Inc. (KRMD) Core Values

You want to know if KORU Medical Systems, Inc.'s values are just words on a page or if they drive the business. The direct takeaway is that their core values-Patient Focus, Innovation, Quality, Collaboration, and Integrity-are measurably tied to their 2025 strategic execution, particularly their growth in the core subcutaneous immunoglobulin (SCIg) market and their expansion into new therapy areas.

This alignment is what's driving the raised full-year 2025 revenue guidance of $40.5 million to $41.0 million, representing a strong 20% to 22% year-over-year growth. That's a solid signal of value-driven performance.

Patient Focus

Patient Focus is the foundation, not just a feel-good slogan. KORU Medical Systems' mission is to empower patients with the freedom to truly live, which means shifting complex treatments from the clinic to the home. The flagship Freedom Syringe Infusion System is the primary tool for this, allowing patients with chronic illnesses like Primary Immunodeficiencies (PIDD) to self-administer life-saving immunoglobulin therapies at home.

This focus is a clear business driver, too. The core business, which centers on these patient-centric solutions, saw net revenues of $9.8 million in Q3 2025, a 30% increase over the prior year period. That's a defintely strong indication that making things easier for the patient is also good for the bottom line.

• Improve patient outcomes and quality of life.
• Provide safe, convenient home-use subcutaneous infusions.

Innovation

You can't stay ahead in MedTech without concrete innovation, and KORU Medical Systems is committed to developing new and improved medical solutions. They are actively advancing their product pipeline beyond the current Freedom System, with plans for a next-generation infusion pump and consumable system to meet future large-volume drug delivery needs.

This value is backed by significant R&D activity. They have 9 active collaborations to add new drugs and indications to the Freedom System, expanding their total addressable market (TAM) beyond the core SCIg market into new therapy areas like oncology. They also announced a new development agreement in Q3 2025 specifically for innovation in Subcutaneous Immunoglobulin Infusion Systems, showing a continuous push for product evolution [cite: 11 (from previous search)].

Quality

In medical devices, quality is non-negotiable; it's a commitment to maintaining high standards in product development and manufacturing. For KORU Medical Systems, this translates directly into operational discipline and margin resilience.

Here's the quick math: The company has reiterated its full-year 2025 gross margin guidance to be between 61% and 63% [cite: 4 (from previous search), 3 (from previous search)]. While Q3 2025 gross margin was 60.2% due to higher manufacturing costs and sales mix, maintaining a target in the low-to-mid 60s is a testament to the quality and premium nature of their products, like the FREEDOM60 and FreedomEdge Syringe Infusion Drivers [cite: 4 (from previous search), 6].

Collaboration

The company's growth strategy hinges on effective Collaboration, which means working effectively with partners and stakeholders. They leverage a Pharma Services and Clinical Trials (PST) business model that partners with biopharmaceutical companies to customize the Freedom System for new drug categories.

The results are clear. In Q3 2025 alone, KORU Medical Systems announced two new PST collaborations, creating opportunities to reach broader patient populations and expand their market footprint [cite: 4 (from previous search)]. This strategy allows them to scale efficiently without the capital-intensive spend of a traditional pharmaceutical company. You can learn more about the strategic implications of these partnerships in Exploring KORU Medical Systems, Inc. (KRMD) Investor Profile: Who's Buying and Why?

Integrity

Integrity is the bedrock of a publicly traded medical device company, defined as operating with honesty, transparency, and ethical conduct. This value is demonstrated through their commitment to strong corporate governance and citizenship.

A concrete action is their governance structure. For instance, the 2025 Proxy Statement details a process where director nominees are considered based on a range of criteria, including their commitment to strong corporate governance and citizenship, ensuring ethical oversight starts at the top. Furthermore, the company reported positive adjusted EBITDA of $0.09 million in Q3 2025, a 121% improvement, and narrowed its net loss to $0.8 million [cite: 4 (from previous search)]. This disciplined financial execution, combined with transparent reporting, shows a commitment to financial integrity and shareholder value.